ENPP3-targeted prodrug TCE / Probio - LARVOL DELTA

The discovery and development of a bispecific T cell engager prodrug targeting ENPP3 (AACR 2026) - "Our in vivo studies using an ENPP3+ CDX model with transplanted human PBMCs demonstrated two important points: (i) the prodrug/masked ENPP3-targeted TCE can potently inhibit tumor growth to a comparable level as the unmasked version and clinical benchmarks, and (ii) the prodrug TCE can be dosed at least 100-fold higher than the active drugs without any observed toxicity, suggesting a greatly improved safety profile. Further preclinical development of these ENPP3-targeted prodrug TCE molecules, including pharmacokinetics and toxicity studies in non-human primates, is ongoing."

Bispecific • Genito-urinary Cancer • Hematological Malignancies • Oncology • Renal Cell Carcinoma • Solid Tumor